Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults - PubMed (original) (raw)
Randomized Controlled Trial
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
William M Greenberg et al. J Psychiatr Res. 2009 Mar.
Abstract
Background: Recent preclinical findings, case reports and non-blinded studies have suggested that glutamatergic interventions may be efficacious for Obsessive-Compulsive Disorder (OCD).
Methods: We enrolled 24 adult outpatients with OCD on stabilized treatment regimens in a double-blind trial of adjunctive glycine, an NMDA glutamate receptor agonist. Participants were randomly assigned 1:1 to either placebo or glycine titrated to 60g/day, with follow-up visits scheduled at 4, 8 and 12 weeks. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was the principal outcome measure.
Results: Regimen non-adherence, principally related to complaints about the taste and/or nausea, resulted in only 14 individuals who were evaluable by predetermined criteria. Those receiving glycine (n=5) experienced a mean decrease of 6.04 points in Y-BOCS score, compared with a 1.00 point decrease for those receiving placebo (n=9). Using a hierarchical linear model, compared with placebo, individuals who received glycine had an average 0.82 decrease in Y-BOCS score for each week they remained in the study, not quite reaching statistical significance (p=0.053). Two of those receiving glycine were responders, versus none receiving placebo (p=0.11, ns, Fisher exact). Despite the dropouts, two participants were known to have subsequently continued taking glycine through their regular treating psychiatrist for over a year.
Conclusions: The glycine condition approached efficacy for treatment of OCD in this study, with the high dropout rate related to problems with palatability and small sample size the principal caveats. This may indicate a new strategy for treatment of OCD, although confirmatory studies are clearly needed. (ClinicalTrials.gov NCT00405535.).
Similar articles
- Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Koran LM, et al. J Clin Psychiatry. 2005 Apr;66(4):515-20. J Clin Psychiatry. 2005. PMID: 15816795 Clinical Trial. - High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I, Baruch Y, Barak Y. Rabinowitz I, et al. Int Clin Psychopharmacol. 2008 Jan;23(1):49-53. doi: 10.1097/YIC.0b013e3282f0f0c5. Int Clin Psychopharmacol. 2008. PMID: 18090508 Clinical Trial. - Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA. Chouinard G, et al. Psychopharmacol Bull. 1990;26(3):279-84. Psychopharmacol Bull. 1990. PMID: 2274626 Clinical Trial. - Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence.
Camfield DA, Sarris J, Berk M. Camfield DA, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):887-95. doi: 10.1016/j.pnpbp.2011.02.011. Epub 2011 Feb 23. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21352883 Review. - [Therapeutic strategies for obsessive-compulsive disorder refractory to treatment].
Mussa A. Mussa A. Vertex. 2008 May-Jun;19(79):143-55. Vertex. 2008. PMID: 18997908 Review. Spanish.
Cited by
- Drug treatment of obsessive-compulsive disorder.
Kellner M. Kellner M. Dialogues Clin Neurosci. 2010;12(2):187-97. doi: 10.31887/DCNS.2010.12.2/mkellner. Dialogues Clin Neurosci. 2010. PMID: 20623923 Free PMC article. Review. - Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M. Askari S, et al. BMC Psychiatry. 2022 Jan 12;22(1):34. doi: 10.1186/s12888-021-03642-z. BMC Psychiatry. 2022. PMID: 35022014 Free PMC article. Clinical Trial. - A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.
Grados MA, Atkins EB, Kovacikova GI, McVicar E. Grados MA, et al. Psychol Res Behav Manag. 2015 Apr 28;8:115-31. doi: 10.2147/PRBM.S58601. eCollection 2015. Psychol Res Behav Manag. 2015. PMID: 25995654 Free PMC article. Review. - Nutritional and herbal supplements in the treatment of obsessive compulsive disorder.
Kuygun Karcı C, Gül Celik G. Kuygun Karcı C, et al. Gen Psychiatr. 2020 Mar 11;33(2):e100159. doi: 10.1136/gpsych-2019-100159. eCollection 2020. Gen Psychiatr. 2020. PMID: 32215361 Free PMC article. Review. - The neurobiological link between OCD and ADHD.
Brem S, Grünblatt E, Drechsler R, Riederer P, Walitza S. Brem S, et al. Atten Defic Hyperact Disord. 2014 Sep;6(3):175-202. doi: 10.1007/s12402-014-0146-x. Epub 2014 Jul 14. Atten Defic Hyperact Disord. 2014. PMID: 25017045 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous